ArticleMilitary medicine2026
Drug-Induced Liver Injury with Novel Fat Burner AlbutarexV2 in an Active Duty Sailor.
Article in Military medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury ranges from asymptomatic to liver failure with supplements becoming an increasingly recognized cause. This case highlights the unique supplement, AlbutarexV2, and the severe cholestatic liver injury it induced with resolution occurring in six months. With steadily increasing obesity rates and supplement use, weight-loss supplements are gaining popularity with various claims of increasing energy expenditure or metabolic rate. Recognition of adverse effects from these therapies is critical to aid in identification and cessation of the agent and helping ban harmful supplements. This case demonstrates the danger of "fat-burners" and delineates the protracted and prolonged liver injury of AlbutarexV2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.